From the Department of Allergy, Immunology and Respiratory Medicine, Monash University, The Alfred Hospital.
Correspondence to: Rob G. Stirling, BSc(Hons), MBBCh, Department of Allergy, Immunology and Respiratory Medicine, Monash University, The Alfred Hospital, Commercial Rd, Melbourne, Victoria 3004, Australia; e-mail: email@example.com
Financial/nonfinancial disclosures: The author has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).
© 2012 American College of Chest Physicians
Inhaled corticosteroids (ICSs) and long-acting β-agonists (LABAs) have developed a central role in the management of airways disease in pulmonary medicine. This efficacy derives largely from the ability to suppress lymphocyte- and eosinophil-driven inflammation and the consequent adverse effects on smooth muscle function. The paradigm for assessment of efficacy of these agents in asthma and COPD focuses on airway function and the subjective and symptomatic benefits that ensue from improved airway function.
Martínez-García et al1 report in a recent issue of CHEST (February 2012) a potentially beneficial effect of combined LABA-ICS on dyspnea score and health-related quality of life in non-cystic fibrosis bronchiectasis. Among the population of patients with bronchiectasis, 67% met inclusion criteria (chiefly airflow obstruction without evidence of COPD or asthma) and 37 patients (28%) completed the study. The combination-treated group demonstrated a clinically significant improvement in transition dyspnea index and quality of life (as measured by the St. George Respiratory Questionnaire), whereas no benefit was seen in the high-dose steroid-treated group. Importantly, no clinically significant benefits attributable to ICS were identified, whereas severe adverse events, including exacerbations (seven vs four) and pneumonia (one vs zero) were increased (if nonsignificantly) in the high-dose steroid-treated group along with significantly higher minor adverse events.
Importantly, chemokine and leukocyte function may be crucial elements in bronchiectasis for the development of effective neutrophil- and lymphocyte-mediated immune responses to infection. ICSs previously have been shown to reduce both airway CD4 lymphocytes and IL-8 in COPD,2 whereas in bronchiectasis, high-dose ICSs decreased airway leukocytes but increased bacterial density.3 A large-scale study of ICS in COPD mirrored this infection concern by demonstrating an increased pneumonia risk in ICS-treated patients with COPD.4
Bronchiectasis as an airways disease stands in distinction from other airways diseases. Fixed and progressive airflow obstruction (usually without bronchial hyperresponsiveness) is evident in the setting of recurrent or chronic airway infection and ongoing neutrophilic inflammation.5 Recognizing these characteristics, therefore, challenges the paradigm by which the utility of ICS and LABA is measured in bronchiectasis and suggests the primacy of infection, inflammation, and exacerbations as determinants of outcomes in bronchiectasis.
In the bronchiectasis-ICS story, many questions remain unanswered. The safety and impact on infection and inflammation of ICS are as yet not well described, and definition of these is of fundamental importance. The comparative effects of ICS vs LABA also await elaboration and may require the study of a steroid-naive population randomized to receive placebo, LABA, ICS, or LABA-ICS combination. The authors make an important contribution to this understanding.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.